Genus

GNS · Main Market · Health Care · mcap £1,490m · 2272.0p

Beta Briefing, track record and signals & risks are not ready for Genus yet.

We follow 967 UK small caps and every one of their announcements – often hundreds per company. 71 companies are already wired into a briefing: browse them.

Financials · balance sheet 30 Jun 26 · last twelve months · today’s market value

Source: results 10 Sep 26 ↗

Key figures Cash & debt Profit & cash flow Valuation Returns & quality Latest half-year

Market cap: £1,506m
Owner’s net cash: −£43.1m
Net cash / market cap: -3%
EV ex leases: £1,344m
Revenue: £658.1m
Operating profit: £87.3m
Free cash flow after leases: £43.7m
EV / EBIT: 15.4×
FCF yield: 2.9%
Price / tangible book: 2.45×
ROCE: 10%
Net income (owners): £285.3m

Hover or tap a figure for its formula and the values used – the names are the line names of the key figures below. Extracted automatically from the company's results announcements; check the source before relying on a figure. Not investment advice.

Key figures As reported

Income statement Balance sheet Cash flow

Annual Half-yearly

Standardised line items in £m, comparable across companies; when a later report restated a period, the later figure is shown and marked ^r (hover for the figure first reported). Italic = calculated (LTM, H2 = FY − H1); a year of other than 12 months is marked (15m). Hover a value for its source.

Latest report: FY Jun 26 (twelve months to 30 Jun 26), published 10 Sep 26 · read the results ↗

Source ↗

	2026 £m	2025 £m
REVENUE	658.1	672.8
Adjusted operating profit	94.8	81.1
Adjusting items
– Net IAS 41 valuation movement on biological assets	12.8	(13.3)
– Amortisation of acquired intangible assets	(4.1)	(5.6)
– Impairment of goodwill	–	(1.5)
– Share-based payment expense	(10.4)	(6.9)
Total adjusting items	(1.7)	(27.3)
Exceptional items (net)	(5.8)	(11.4)
Total adjusting items	(7.5)	(38.7)
OPERATING PROFIT	87.3	42.4
Share of post-tax profit of joint ventures and associates retained	34.7	9.1
Other gains and losses	204.3	(4.2)
Finance costs	(16.7)	(21.4)
Finance income	0.9	2.6
PROFIT BEFORE TAX	310.5	28.5
Taxation	(25.0)	(9.2)
PROFIT FOR THE YEAR	285.5	19.3
ATTRIBUTABLE TO
Owners of the Company	285.3	19.3
Non-controlling interest	0.2	–
Total attributable to	285.5	19.3
EARNINGS PER SHARE
Basic earnings per share	431.6p	29.3p
Diluted earnings per share	425.1p	28.9p

Source ↗

	2026 £m	2025 £m
ASSETS
Goodwill	103.4	102.8
Other intangible assets	49.5	55.3
Biological assets	218.7	219.0
Property, plant and equipment	135.2	160.3
Interests in joint ventures and associates	205.3	62.8
Other investments	3.3	3.2
Derivative financial assets	–	–
Other receivables	5.6	10.3
Deferred tax assets	37.7	30.9
TOTAL NON-CURRENT ASSETS	758.7	644.6
Inventories	47.8	46.2
Biological assets	35.9	34.7
Trade and other receivables	120.9	119.2
Cash and cash equivalents	43.7	48.0
Income tax receivable	8.3	6.2
Retirement benefit asset	2.7	–
Derivative financial assets	0.3	0.1
TOTAL CURRENT ASSETS	259.6	254.4
TOTAL ASSETS	1,018.3	899.0
LIABILITIES
Trade and other payables	(95.6)	(107.7)
Interest-bearing loans and borrowings	(4.3)	(2.9)
Provisions	(1.2)	(0.4)
Deferred consideration	(2.7)	(2.6)
Obligations under leases	(9.8)	(13.3)
Tax liabilities	(3.5)	(2.2)
Derivative financial liabilities	(0.1)	(2.2)
TOTAL CURRENT LIABILITIES	(117.2)	(131.3)
Trade and other payables	–	(0.1)
Interest-bearing loans and borrowings	(77.0)	(215.9)
Retirement benefit obligations	(7.1)	(6.9)
Provisions	(1.8)	(0.3)
Deferred consideration	(5.5)	(7.9)
Deferred tax liabilities	(25.7)	(25.8)
Derivative financial liabilities	(0.9)	(1.0)
Obligations under leases	(16.4)	(33.8)
TOTAL NON-CURRENT LIABILITIES	(134.4)	(291.7)
TOTAL LIABILITIES	(251.6)	(423.0)
NET ASSETS	766.7	476.0
EQUITY
Called-up share capital	6.7	6.6
Share premium account	179.1	179.1
Own shares	(0.1)	(0.1)
Translation reserve	(13.0)	(30.8)
Hedging reserve	0.1	(0.3)
Retained earnings	593.9	321.6
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY	766.7	476.1
Non-controlling interest	0.5	0.4
Put option over non-controlling interest	(0.5)	(0.5)
TOTAL NON-CONTROLLING INTEREST	–	(0.1)
TOTAL EQUITY	766.7	476.0

Source ↗

	2026 £m	2025 £m
NET CASH FLOW FROM OPERATING ACTIVITIES	74.4	67.2
CASH FLOWS FROM INVESTING ACTIVITIES
Dividends received from joint ventures and associates	16.1	6.1
Disposal of subsidiary investment	–	1.3
Net cash flow from the sale of 51% of PIC China after taxation	97.7	–
Acquisition of other investments	–	(2.4)
Payment of deferred consideration	–	(0.6)
Purchase of property, plant and equipment	(12.5)	(13.4)
Purchase of intangible assets	(5.6)	(5.2)
Proceeds from sale of property, plant and equipment	2.1	0.4
NET CASH INFLOW/(OUTFLOW) FROM INVESTING ACTIVITIES	97.8	(13.8)
CASH FLOWS FROM FINANCING ACTIVITIES
Drawdown of borrowings	175.8	152.8
Repayment of borrowings	(316.4)	(158.2)
Payment of lease liabilities	(12.6)	(14.1)
Equity dividends paid	(21.7)	(21.1)
Purchase of non-controlling interest in De Novo Genetics LLC	(2.7)	(2.6)
Dividend to non-controlling interest	–	(0.1)
Issue of share capital	0.1	–
Debt issue costs	(0.5)	(3.3)
NET CASH OUTFLOW FROM FINANCING ACTIVITIES	(178.0)	(46.6)
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS	(5.8)	6.8
Cash and cash equivalents at start of the year	48.0	42.5
Net (decrease)/increase in cash and cash equivalents	(5.8)	6.8
Effect of exchange rate fluctuations on cash and cash equivalents	1.5	(1.3)
TOTAL CASH AND CASH EQUIVALENTS AT 30 JUNE	43.7	48.0

Source ↗

	Six months ended 31 December 2025 £m	Six months ended 31 December 2024 £m	Year ended 30 June 2025 £m
REVENUE	335.6	336.4	672.8
Adjusted operating profit	55.8	40.3	81.1
Adjusting items
- Net IAS 41 valuation movement on biological assets	(6.4)	(16.0)	(13.3)
- Amortisation of acquired intangible assets	(2.4)	(2.9)	(5.6)
- Impairment of goodwill	-	-	(1.5)
- Share-based payment expense	(4.5)	(2.9)	(6.9)
Total adjusting items	(13.3)	(21.8)	(27.3)
Exceptional items (net)	(6.7)	(6.0)	(11.4)
Total adjusting items	(20.0)	(27.8)	(38.7)
OPERATING PROFIT	35.8	12.5	42.4
Share of post-tax profit of joint ventures and associates retained	12.4	5.1	9.1
Other gains and losses	-	(4.5)	(4.2)
Finance costs	(9.2)	(11.3)	(21.4)
Finance income	0.5	1.5	2.6
PROFIT BEFORE TAX	39.5	3.3	28.5
Taxation	(9.6)	(1.8)	(9.2)
PROFIT FOR THE PERIOD	29.9	1.5	19.3
ATTRIBUTABLE TO
Owners of the Company	29.8	1.6	19.3
Non-controlling interest	0.1	(0.1)	-
Total attributable to	29.9	1.5	19.3
EARNINGS PER SHARE
Basic earnings per share	45.1p	2.4p	29.3p
Diluted earnings per share	44.5p	2.4p	28.9p

Source ↗

	31 December 2025 £m	(restated) 1 31 December 2024 £m	30 June 2025 £m
ASSETS
Goodwill	101.9	109.4	102.8
Other intangible assets	52.0	61.0	55.3
Biological assets	210.0	235.7	219.0
Property, plant and equipment	137.0	169.6	160.3
Interests in joint ventures and associates	73.3	63.0	62.8
Other investments	3.2	3.6	3.2
Derivative financial assets	-	0.6	-
Other receivables	8.5	11.3	10.3
Deferred tax assets	31.5	28.9	30.9
TOTAL NON-CURRENT ASSETS	617.4	683.1	644.6
Inventories	47.4	51.8	46.2
Biological assets	26.8	30.1	34.7
Trade and other receivables	121.9	128.4	119.2
Cash and cash equivalents	43.4	47.4	48.0
Income tax receivable	9.8	2.9	6.2
Derivative financial assets	-	1.1	0.1
Assets classified as held for sale	54.6	-	-
TOTAL CURRENT ASSETS	303.9	261.7	254.4
TOTAL ASSETS	921.3	944.8	899.0
LIABILITIES
Trade and other payables	(84.5)	(111.0)	(107.7)
Interest-bearing loans and borrowings	(4.5)	(4.0)	(2.9)
Provisions	(0.2)	(0.7)	(0.4)
Deferred consideration	(2.7)	(2.8)	(2.6)
Obligations under leases	(10.1)	(12.9)	(13.3)
Tax liabilities	(6.7)	(2.8)	(2.2)
Derivative financial liabilities	(0.1)	(0.8)	(2.2)
Liabilities directly associated with assets classified as held for sale	(26.0)	-	-
TOTAL CURRENT LIABILITIES	(134.8)	(135.0)	(131.3)
Trade and other payables	(0.1)	-	(0.1)
Interest-bearing loans and borrowings	(229.1)	(244.6)	(215.9)
Retirement benefit obligations	(7.1)	(6.5)	(6.9)
Provisions	(0.1)	(0.3)	(0.3)
Deferred consideration	(5.4)	(8.6)	(7.9)
Deferred tax liabilities	(21.7)	(26.6)	(25.8)
Derivative financial liabilities	(2.1)	(1.1)	(1.0)
Obligations under leases	(17.0)	(36.1)	(33.8)
TOTAL NON-CURRENT LIABILITIES	(282.6)	(323.8)	(291.7)
TOTAL LIABILITIES	(417.4)	(458.8)	(423.0)
NET ASSETS	503.9	486.0	476.0
EQUITY
Called-up share capital	6.7	6.6	6.6
Share premium account	179.1	179.1	179.1
Own shares	(0.1)	(0.1)	(0.1)
Translation reserve	(22.4)	(6.7)	(30.8)
Hedging reserve	(0.3)	0.5	(0.3)
Retained earnings	341.0	306.8	321.6
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY	504.0	486.2	476.1
Non-controlling interest	0.4	0.3	0.4
Put option over non-controlling interest	(0.5)	(0.5)	(0.5)
TOTAL NON-CONTROLLING INTEREST	(0.1)	(0.2)	(0.1)
TOTAL EQUITY	503.9	486.0	476.0

Source ↗

	Six months ended 31 December 2025 £m	Six months ended 31 December 2024 £m	Year ended 30 June 2025 £m
NET CASH FLOW FROM OPERATING ACTIVITIES	22.7	25.5	67.2
CASH FLOWS FROM INVESTING ACTIVITIES
Dividends received from joint ventures and associates	0.2	-	6.1
Joint venture and associate loan repayment	-	0.1	-
Payment of deferred consideration	-	(0.6)	(0.6)
Disposal of subsidiary investment	-	1.3	1.3
Acquisition of other investments	-	(2.4)	(2.4)
Purchase of property, plant and equipment	(5.3)	(5.2)	(13.4)
Purchase of intangible assets	(2.4)	(2.5)	(5.2)
Proceeds from sale of property, plant and equipment	0.2	0.4	0.4
NET CASH OUTFLOW FROM INVESTING ACTIVITIES	(7.3)	(8.9)	(13.8)
CASH FLOWS FROM FINANCING ACTIVITIES
Drawdown of borrowings	93.4	86.4	152.8
Repayment of borrowings	(80.8)	(70.5)	(158.2)
Payment of lease liabilities	(7.2)	(7.9)	(14.1)
Equity dividends paid	(14.3)	(14.3)	(21.1)
Purchase of non-controlling interest in De-Novo Genetic LLC	(2.7)	(2.6)	(2.6)
Equity issued	0.1	-	-
Dividend to non-controlling interest	-	(0.1)	(0.1)
Debt issue costs	(0.5)	(0.7)	(3.3)
NET CASH OUTFLOW FROM FINANCING ACTIVITIES	(12.0)	(9.7)	(46.6)
NET INCREASE IN CASH AND CASH EQUIVALENTS	3.4	6.9	6.8
Cash and cash equivalents at start of period	48.0	42.5	42.5
Net increase in cash and cash equivalents	3.4	6.9	6.8
Effect of exchange rate fluctuations on cash and cash equivalents	0.8	(2.0)	(1.3)
TOTAL CASH AND CASH EQUIVALENTS AT END OF PERIOD	52.2	47.4	48.0
INCLUDED IN ASSETS CLASSIFIED AS HELD FOR SALE	8.8	-	-
CASH AND CASH EQUIVALENTS AT END OF PERIOD	43.4	47.4	48.0

	FY Jun 26	FY Jun 25
Revenue to operating profit
Revenue	658.1	672.8
Adjusted EBITDA	130.9	119.8
Adjusted operating profit	94.8	81.1
Exceptional / adjusting items	(5.8)	(11.4)
Operating profit	87.3	42.4
Share-based payments	(10.4)	(6.9)
Operating profit to net income
Finance costs	(16.7)	(21.4)
Profit before tax	310.5	28.5
Tax	(25.0)	(9.2)
Net income (owners)	285.3	19.3
Per share
EPS basic	431.6p	29.3p
EPS diluted	425.1p	28.9p
Dividend per share	35.2p	32.0p

	H2 Jun 26	H1 Dec 25	H2 Jun 25	H1 Dec 24
Revenue to operating profit
Revenue	322.5	335.6	336.4	336.4
Adjusted operating profit	39.0	55.8	40.8	40.3
Exceptional / adjusting items	0.9	(6.7)	(5.4)	(6.0)
Operating profit	51.5	35.8	29.9	12.5
Share-based payments	(5.9)	(4.5)	(4.0)	(2.9)
Operating profit to net income
Finance costs	(7.5)	(9.2)	(10.1)	(11.3)
Profit before tax	271.0	39.5	25.2	3.3
Tax	(15.4)	(9.6)	(7.4)	(1.8)
Net income (owners)	255.5	29.8	17.7	1.6
Per share
EPS basic	386.5p	45.1p	26.9p	2.4p
EPS diluted	380.6p	44.5p	26.5p	2.4p
Dividend per share	24.0p	11.2p	21.7p	10.3p

	FY Jun 26	FY Jun 25
Operating activities
Cash from operations	74.4	67.2
Tax paid	–	20.7
Investing activities
Capex (PP&E)	(12.5)	(13.4)
Capex (intangibles)	(5.6)	(5.2)
Financing activities
Lease principal paid	(12.6)	(14.1)
Dividends paid	(21.7)	(21.1)
Shares issued	0.1	0.0

	H2 Jun 26	H1 Dec 25	H2 Jun 25	H1 Dec 24
Operating activities
Cash from operations	51.7	22.7	41.7	25.5
Tax paid	–	10.9	11.2	9.5
Investing activities
Capex (PP&E)	(7.2)	(5.3)	(8.2)	(5.2)
Capex (intangibles)	(3.2)	(2.4)	(2.7)	(2.5)
Financing activities
Lease principal paid	(5.4)	(7.2)	(6.2)	(7.9)
Dividends paid	(7.4)	(14.3)	(6.8)	(14.3)
Shares issued	0.0	0.1	–	–

	30 Jun 26	30 Jun 25
Non-current assets
Goodwill	103.4	102.8
Other intangibles	49.5	55.3
Property, plant & equipment	135.2	160.3
Associates & JVs	205.3	62.8
Other investments	3.3	3.2
Non-current assets	758.7	644.6
Current assets
Inventories	47.8	46.2
Trade receivables	120.9	119.2
Cash	43.7	48.0
Current assets	259.6	254.4
Total assets	1,018.3	899.0
Current liabilities
Trade payables	95.6	107.7
Borrowings, current	4.3	2.9
Lease liabilities, current	9.8	13.3
Current liabilities	117.2	131.3
Non-current liabilities
Borrowings, non-current	77.0	215.9
Lease liabilities, non-current	16.4	33.8
Deferred consideration	5.5	7.9^r
Pension surplus / (deficit)	–	(6.9)
Non-current liabilities	134.4	291.7
Total liabilities	251.6	423.0
Equity
Non-controlling interests	0.0	(0.1)
Total equity	766.7	476.0
Net cash and other figures
Net cash / (debt) incl. leases	(71.8)	(228.2)
Undrawn facilities	263.8	119.4

	30 Jun 26	31 Dec 25	30 Jun 25	31 Dec 24
Non-current assets
Goodwill	103.4	101.9	102.8	109.4
Other intangibles	49.5	52.0	55.3	61.0
Property, plant & equipment	135.2	137.0	160.3	169.6
Associates & JVs	205.3	73.3	62.8	63.0
Other investments	3.3	3.2	3.2	3.6
Non-current assets	758.7	617.4	644.6	683.1
Current assets
Inventories	47.8	47.4	46.2	51.8
Trade receivables	120.9	121.9	119.2	128.4
Cash	43.7	43.4	48.0	47.4
Current assets	259.6	303.9	254.4	261.7
Total assets	1,018.3	921.3	899.0	944.8
Current liabilities
Trade payables	95.6	84.5	107.7	111.0
Borrowings, current	4.3	4.5	2.9	4.0
Lease liabilities, current	9.8	10.1	13.3	12.9
Current liabilities	117.2	134.8	131.3	135.0
Non-current liabilities
Borrowings, non-current	77.0	229.1	215.9	244.6
Lease liabilities, non-current	16.4	17.0	33.8	36.1
Deferred consideration	5.5	2.7	7.9^r	2.8
Pension surplus / (deficit)	–	(7.1)	(6.9)	(6.5)
Non-current liabilities	134.4	282.6	291.7	323.8
Total liabilities	251.6	417.4	423.0	458.8
Equity
Non-controlling interests	0.0	(0.1)	(0.1)	(0.2)
Total equity	766.7	503.9	476.0	486.0
Net cash and other figures
Net cash / (debt) incl. leases	(71.8)	(232.9)	(228.2)	–
Undrawn facilities	263.8	–	119.4	–

Read automatically from each results announcement. Check the source before relying on a figure.

Spotted an error in this income statement? Report it

Company filings. Not investment advice.